NCT07048197 - A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

September 15, 2028

Study Completion Date

September 15, 2028

Conditions

Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

Interventions

BIOLOGICAL

Rapcabtagene autoleucel

Single infusion of Rapcabtagene autoleucel

Trial Locations (6)

RECRUITING

Novartis Investigative Site, Berlin

RECRUITING

Novartis Investigative Site, Madrid

RECRUITING

Novartis Investigative Site, Bordeaux

RECRUITING

Novartis Investigative Site, Ulm

RECRUITING

Novartis Investigative Site, Le Kremlin-Bicêtre

RECRUITING

Novartis Investigative Site, Singapore